Literature DB >> 27559122

Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.

Kate Buchacz1, Bryan Lau2, Yuezhou Jing2, Ronald Bosch3, Alison G Abraham2, M John Gill4, Michael J Silverberg5, James J Goedert6, Timothy R Sterling7, Keri N Althoff2, Jeffrey N Martin8, Greer Burkholder9, Neel Gandhi10, Hasina Samji11, Pragna Patel1, Anita Rachlis12, Jennifer E Thorne2, Sonia Napravnik13, Keith Henry14, Angel Mayor15, Kelly Gebo2, Stephen J Gange2, Richard D Moore2, John T Brooks1.   

Abstract

BACKGROUND: There are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immunodeficiency virus (HIV)-infected patients in care in the United States and Canada.
METHODS: We studied HIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) during 2000-2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral therapy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, "person-years") with 95% confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000-2003, 2004-2007, and 2008-2010.
RESULTS: A total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation during 2000-2003, 2004-2007, and 2008-2010, respectively (Ptrend<.001); the rates of most individual OIs decreased as well. During 2008-2010, the leading OIs included Pneumocystis jiroveci pneumonia, esophageal candidiasis, and disseminated Mycobacterium avium complex or Mycobacterium kansasii infection.
CONCLUSIONS: For HIV-infected persons in care during 2000-2010, rates of first OI were relatively low and generally declined over this time. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  AIDS-related opportunistic infections; CD4+ T-lymphocyte count; HIV cohort studies; combination antiretroviral therapy; epidemiology; incidence; prophylaxis

Mesh:

Year:  2016        PMID: 27559122      PMCID: PMC4996145          DOI: 10.1093/infdis/jiw085

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Authors:  Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore
Journal:  Int J Epidemiol       Date:  2007-01-08       Impact factor: 7.196

Review 2.  HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines.

Authors:  John T Brooks; Jonathan E Kaplan; King K Holmes; Constance Benson; Alice Pau; Henry Masur
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

3.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3.

Authors:  Bryan Lau; Stephen J Gange; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

7.  Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.

Authors:  Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

8.  The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

Authors:  A Mocroft; H J Furrer; J M Miro; P Reiss; C Mussini; O Kirk; S Abgrall; S Ayayi; B Bartmeyer; D Braun; A Castagna; A d'Arminio Monforte; B Gazzard; F Gutierrez; I Hurtado; K Jansen; L Meyer; P Muñoz; N Obel; P Soler-Palacin; A Papadopoulos; F Raffi; J T Ramos; J K Rockstroh; D Salmon; C Torti; J Warszawski; S de Wit; R Zangerle; C Fabre-Colin; J Kjaer; G Chene; J Grarup; J D Lundgren
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

9.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

10.  Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).

Authors:  Marguerite Guiguet; Kholoud Porter; Andrew Phillips; Dominique Costagliola; Abdel Babiker
Journal:  Open AIDS J       Date:  2008-02-12
View more
  32 in total

1.  Mycobacterium avium complex infection presenting as persistent ascites.

Authors:  Bourne L Auguste; Ashish D Patel; Reed A Siemieniuk
Journal:  CMAJ       Date:  2018-04-03       Impact factor: 8.262

2.  Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

Authors:  John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana
Journal:  Blood Adv       Date:  2021-01-12

3.  Genotyping of Pneumocystis jirovecii by Use of a New Simplified Nomenclature System Based on the Internal Transcribed Spacer Regions and 5.8S rRNA Gene of the rRNA Operon.

Authors:  Ting Xue; Zhuang Ma; Fan Liu; Wei-Qin Du; Li He; Liang Ma; Chun-Li An
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

4.  Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Joseph J Eron; Stephen R Cole; David van Duin; David A Wohl; Brenna C Hogan; Keri N Althoff; Kelly A Gebo; Richard D Moore; Michael J Silverberg; Michael A Horberg; M John Gill; W Christopher Mathews; Marina B Klein; Jonathan A Colasanti; Timothy R Sterling; Angel M Mayor; Peter F Rebeiro; Kate Buchacz; Jun Li; Ni Gusti Ayu Nanditha; Jennifer E Thorne; Ank Nijhawan; Stephen A Berry
Journal:  J Infect Dis       Date:  2020-12-26       Impact factor: 5.226

5.  Possible Diagnostic Delays and Missed Prevention Opportunities in Pneumocystis Pneumonia Patients Without HIV: Analysis of Commercial Insurance Claims Data-United States, 2011-2015.

Authors:  Jeremy A W Gold; Brendan R Jackson; Kaitlin Benedict
Journal:  Open Forum Infect Dis       Date:  2020-06-29       Impact factor: 3.835

6.  The trophic life cycle stage of Pneumocystis species induces protective adaptive responses without inflammation-mediated progression to pneumonia.

Authors:  Heather M Evans; Beth A Garvy
Journal:  Med Mycol       Date:  2018-11-01       Impact factor: 4.076

7.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

Review 8.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

9.  Granulomatous Pneumocystis jiroveci Pneumonia in an HIV-Positive Patient on Antiretroviral Therapy: A Diagnostic Challenge.

Authors:  Montserrat Diaz-Abad; Kathryn S Robinett; Anayansi Lasso-Pirot; Teklu B Legesse; Mariam Khambaty
Journal:  Open Respir Med J       Date:  2021-06-18

Review 10.  Treatment and Prevention of Histoplasmosis in Adults Living with HIV.

Authors:  David S McKinsey
Journal:  J Fungi (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.